Literature DB >> 10736096

Monocytes secrete interleukin-6 when co-cultured in vitro with benign or malignant autologous fragment spheroids from squamous cell carcinoma patients.

J Heimdal1, H J Aarstad, J Olofsson.   

Abstract

Biopsies from tumour and benign mucosa were removed from patients with head and neck squamous-cell carcinoma (HNSCC), chopped into cubes and transferred to a nonadhesive culture system where in vitro fragment (F)-spheroids were established. The F-spheroids stabilized within 14 days of culture in vitro with epithelial cells and fibroblasts on the surface. F-spheroids were co-cultured with freshly isolated autologous monocytes. The monocytes of 10 of 11 patients secreted interleukin (IL)-6 at a level similar to that of the average monocyte endotoxin-stimulated response. Secreted IL-1beta or tumour necrosis factor-alpha (TNF-alpha) levels greater than 0.1 times the endotoxin-stimulated secretion were determined in one and two of the 11 co-culture experiments, respectively. This different monocyte response to F-spheroids compared with endotoxin stimulation was also present at the mRNA expression level. HNSCC monocytes secreted no IL-6 after co-culture with autologous fibroblasts. When monocytes and F-spheroids were cultured separated by a semipermeable membrane, the IL-6 supernatant level was only approximately 25% of that observed during co-culture with direct contact. F-spheroids secreted only trace amounts of IL-6. In conclusion, monocytes of HNSCC patients generally secrete IL-6, but not IL-1beta or TNF-alpha, after stimulation with epithelial-associated components of F-spheroids upon direct contact and in part by a soluble substance.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10736096     DOI: 10.1046/j.1365-3083.2000.00680.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  7 in total

1.  Viable head and neck tumor spheroids stimulate in vitro autologous monocyte MCP-1 secretion through soluble substances and CD14/lectin-like receptors.

Authors:  Carla Olsnes; John-Helge Heimdal; Kenneth W Kross; Jan Olofsson; Hans Jørgen Aarstad
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-11-19       Impact factor: 2.503

2.  Evaluation of spheroid head and neck squamous cell carcinoma cell models in comparison to monolayer cultures.

Authors:  Lorenz Kadletz; Gregor Heiduschka; Julian Domayer; Rainer Schmid; Elisabeth Enzenhofer; Dietmar Thurnher
Journal:  Oncol Lett       Date:  2015-07-14       Impact factor: 2.967

Review 3.  [Preclinical models in head and neck tumors : Evaluation of cellular and molecular resistance mechanisms in the tumor microenvironment].

Authors:  A Affolter; J Hess
Journal:  HNO       Date:  2016-12       Impact factor: 1.284

4.  A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance.

Authors:  Ki-Up Kim; Shannon M Wilson; Keith S Abayasiriwardana; Rodney Collins; Lars Fjellbirkeland; Zhidong Xu; David M Jablons; Stephen L Nishimura; V Courtney Broaddus
Journal:  Am J Respir Cell Mol Biol       Date:  2005-08-25       Impact factor: 6.914

Review 5.  Spherical cancer models in tumor biology.

Authors:  Louis-Bastien Weiswald; Dominique Bellet; Virginie Dangles-Marie
Journal:  Neoplasia       Date:  2015-01       Impact factor: 5.715

Review 6.  Feasibility of Primary Tumor Culture Models and Preclinical Prediction Assays for Head and Neck Cancer: A Narrative Review.

Authors:  Amy J C Dohmen; Justin E Swartz; Michiel W M Van Den Brekel; Stefan M Willems; René Spijker; Jacques Neefjes; Charlotte L Zuur
Journal:  Cancers (Basel)       Date:  2015-08-28       Impact factor: 6.639

Review 7.  Management and potentialities of primary cancer cultures in preclinical and translational studies.

Authors:  Giacomo Miserocchi; Laura Mercatali; Chiara Liverani; Alessandro De Vita; Chiara Spadazzi; Federica Pieri; Alberto Bongiovanni; Federica Recine; Dino Amadori; Toni Ibrahim
Journal:  J Transl Med       Date:  2017-11-07       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.